荷兰全国性研究:感染性腹主动脉瘤开放与腔内修复比较
结果显示两组30天死亡率分别为1/13和0/13,1年随访期间OR组1例死亡、EVAR组1例主要再干预,总体临床结局可接受。
要点
- MAAA占所有登记腹主动脉瘤的0.7%。
- OR与EVAR的30天死亡率分别为1/13和0/13。
- 1年随访中两组再入院率相近(OR 36.4% vs EVAR 33.3%)。
核心结论
- OR和EVAR治疗的MAAA患者在30天和1年随访时均显示可接受的临床结局。
- 根据患者的临床病程,可考虑将EVAR用于该疾病的管理。
研究设计与样本
- 回顾性队列研究,纳入2016年荷兰外科动脉瘤审计中登记的所有腹主动脉瘤中心。
主要发现
- MAAA发生率为所有登记腹主动脉瘤的0.7%。
- OR组30天死亡1/13,EVAR组30天死亡0/13。
- 30天内主要再干预:OR组1例、EVAR组1例;次要再干预:OR组1例、EVAR组1例。
- 30天内再入院:OR组2例(15.4%),EVAR组1例(7.7%)。
- 1年随访共23例可用:OR组死亡1例(9.1%);EVAR组主要再干预1例(移除内支架并行螺旋静脉重建);次要再干预OR组2例(18.2%)、EVAR组2例(16.7%);1年内再入院OR组4例(36.4%)、EVAR组4例(33.3%)。
临床怎么用
- 对于MAAA患者,OR和EVAR均可作为治疗选择,需根据患者临床病程个体化决策。
- EVAR可作为MAAA管理的一种考虑方案。
局限性
- 为回顾性研究,依赖问卷收集结局数据。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Mycotic aneurysms of the abdominal aorta (MAAA) can be treated by open repair (OR) or endovascular aneurysm repair (EVAR). This nationwide study provides an overview of the situation of MAAA treatment in The Netherlands in 2016. METHODS: A retrospective cohort study was conducted with all centers that registered aortic abdominal aneurysms in the Dutch Surgical Aneurysm Audit in 2016. Questionnaires on 1-year outcomes were sent to all centers that treated patients with MAAA. The primary aim was to determine 30-day and 1-year mortality and morbidity of OR- and EVAR-treated patients. Morbidity was determined by the need for reoperations and the number of readmissions to the hospital. RESULTS: Twenty-six MAAA were detected in the Dutch Surgical Aneurysm Audit database of 2016, resulting in an incidence of 0.7% of all registered abdominal aortic aneurysms. The 30-day mortality for OR and EVAR treated patients was 1 in 13 and 0 in 13, respectively. Major and minor reinterventions within 30 days were needed for two (one OR and one EVAR) and two (one OR and one EVAR) patients, respectively. Two patients (15.4%) in the OR group and one patient (7.7%) in the EVAR group were readmitted to hospital within 30 days. In total, 1-year outcomes of 23 patients were available. In the OR group, one patient (9.1%) died in the first postoperative year. There was one major reintervention (removal of endoprosthesis and spiralvein reconstruction) in the EVAR group. Two patients (18.2%) treated with OR and two (16.7%) treated with EVAR required a minor reintervention. In both groups, four patients (OR, 36.4%; EVAR, 33.3%) were readmitted to hospital within 1 year postoperatively. CONCLUSIONS: Both OR- and EVAR-treated patients show acceptable clinical outcomes after 30 days and at the 1-year follow-up. Depending on the clinical course of the patient, EVAR may be considered in the management of this disease.
引用
- Dang Q, Statius van Eps RG, Wever JJ, et al. Nationwide study of the treatment of mycotic abdominal aortic aneurysms comparing open and endovascular repair in The Netherlands. J Vasc Surg. 2020. PMID: 32061482. doi:10.1016/j.jvs.2019.09.060
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。